Zinc supplementation as an adjunct therapy for COVID‐19: Challenges and opportunities. Issue 10 (2nd June 2021)
- Record Type:
- Journal Article
- Title:
- Zinc supplementation as an adjunct therapy for COVID‐19: Challenges and opportunities. Issue 10 (2nd June 2021)
- Main Title:
- Zinc supplementation as an adjunct therapy for COVID‐19: Challenges and opportunities
- Authors:
- Chinni, Vidyasagar
El‐Khoury, John
Perera, Marlon
Bellomo, Rinaldo
Jones, Daryl
Bolton, Damien
Ischia, Joseph
Patel, Oneel - Abstract:
- Abstract : An outbreak of a novel coronavirus (COVID‐19 or 2019‐CoV) infection has posed significant threats to international health and the economy. Patients with COVID‐19 are at risk of cytokine storm, acute respiratory distress syndrome (ARDS), reduced blood oxygenation, mechanical ventilation, and a high death rate. Although recent studies have shown remdesivir and dexamethasone as treatment options, there is an urgent need to find a treatment to inhibit virus replication and to control the progression of the disease. Essential biometal zinc has generated a lot of excitement as one of the promising candidates to reduce the severity of COVID‐19 infection. Several published observations outlined in the review are the reasons why there is a global enthusiasm that zinc therapy could be a possible therapeutic option. However, the biggest challenge in realising the therapeutic value of zinc is lack of optimal treatment modalities such as dose, duration of zinc supplementation and the mode of delivery. In this review, we discuss the regulatory mechanism that hinges upon the bioavailability of zinc. Finally, we propose that intravenous zinc could circumvent the confounding factors affecting the bioavailability of zinc and allow zinc to achieve its therapeutic potential. If successful, due to advantages such as lack of toxicity, low cost and ease of availability, intravenous zinc could be rapidly implemented clinically.
- Is Part Of:
- British journal of clinical pharmacology. Volume 87:Issue 10(2021)
- Journal:
- British journal of clinical pharmacology
- Issue:
- Volume 87:Issue 10(2021)
- Issue Display:
- Volume 87, Issue 10 (2021)
- Year:
- 2021
- Volume:
- 87
- Issue:
- 10
- Issue Sort Value:
- 2021-0087-0010-0000
- Page Start:
- 3737
- Page End:
- 3746
- Publication Date:
- 2021-06-02
- Subjects:
- bioavailability -- COVID‐19 -- immunity -- intravenous -- oral -- SARS‐COV‐2 -- zinc
Pharmacology -- Periodicals
Drugs -- Periodicals
615.1 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2125 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/bcp.14826 ↗
- Languages:
- English
- ISSNs:
- 0306-5251
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2307.180000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 18987.xml